Cargando…
The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis
Chronic pancreatitis (CP) is a chronic progressive inflammatory disease of the pancreas, caused by multiple factors and accompanied by irreversible impairment of pancreatic internal and external secretory functions. Pathologically, atrophy of the pancreatic acini, tissue fibrosis or calcification, f...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730810/ https://www.ncbi.nlm.nih.gov/pubmed/36505827 http://dx.doi.org/10.3389/fonc.2022.1050274 |
_version_ | 1784845764124475392 |
---|---|
author | Li, Bing-Qing Liu, Xin-Yuan Mao, Tao Zheng, Tao-Hua Zhang, Peng Zhang, Qi Zhang, Yu Li, Xiao-Yu |
author_facet | Li, Bing-Qing Liu, Xin-Yuan Mao, Tao Zheng, Tao-Hua Zhang, Peng Zhang, Qi Zhang, Yu Li, Xiao-Yu |
author_sort | Li, Bing-Qing |
collection | PubMed |
description | Chronic pancreatitis (CP) is a chronic progressive inflammatory disease of the pancreas, caused by multiple factors and accompanied by irreversible impairment of pancreatic internal and external secretory functions. Pathologically, atrophy of the pancreatic acini, tissue fibrosis or calcification, focal edema, inflammation, and necrosis are observed. Clinical manifestations include recurrent or persistent abdominal pain, diarrhea, emaciation, and diabetes. In addition, CP is prone to develop into pancreatic cancer(PC) due to persistent inflammation and fibrosis. The disease course is prolonged and the clinical prognosis is poor. Currently, clinical treatment of CP is still based on symptomatic treatment and there is a lack of effective etiological treatment. Encouragingly, experiments have shown that a variety of active substances have great potential in the etiological treatment of chronic pancreatitis. In this paper, we will review the pathogenesis of CP, as well as the research progress on anti-inflammatory and anti-fibrotic therapies, which will provide new ideas for the development of subsequent clinical studies and formulation of effective treatment programs, and help prevent CP from developing into pancreatic cancer and reduce the prevalence of PC as much as possible. |
format | Online Article Text |
id | pubmed-9730810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97308102022-12-09 The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis Li, Bing-Qing Liu, Xin-Yuan Mao, Tao Zheng, Tao-Hua Zhang, Peng Zhang, Qi Zhang, Yu Li, Xiao-Yu Front Oncol Oncology Chronic pancreatitis (CP) is a chronic progressive inflammatory disease of the pancreas, caused by multiple factors and accompanied by irreversible impairment of pancreatic internal and external secretory functions. Pathologically, atrophy of the pancreatic acini, tissue fibrosis or calcification, focal edema, inflammation, and necrosis are observed. Clinical manifestations include recurrent or persistent abdominal pain, diarrhea, emaciation, and diabetes. In addition, CP is prone to develop into pancreatic cancer(PC) due to persistent inflammation and fibrosis. The disease course is prolonged and the clinical prognosis is poor. Currently, clinical treatment of CP is still based on symptomatic treatment and there is a lack of effective etiological treatment. Encouragingly, experiments have shown that a variety of active substances have great potential in the etiological treatment of chronic pancreatitis. In this paper, we will review the pathogenesis of CP, as well as the research progress on anti-inflammatory and anti-fibrotic therapies, which will provide new ideas for the development of subsequent clinical studies and formulation of effective treatment programs, and help prevent CP from developing into pancreatic cancer and reduce the prevalence of PC as much as possible. Frontiers Media S.A. 2022-11-24 /pmc/articles/PMC9730810/ /pubmed/36505827 http://dx.doi.org/10.3389/fonc.2022.1050274 Text en Copyright © 2022 Li, Liu, Mao, Zheng, Zhang, Zhang, Zhang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Bing-Qing Liu, Xin-Yuan Mao, Tao Zheng, Tao-Hua Zhang, Peng Zhang, Qi Zhang, Yu Li, Xiao-Yu The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis |
title | The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis |
title_full | The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis |
title_fullStr | The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis |
title_full_unstemmed | The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis |
title_short | The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis |
title_sort | research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730810/ https://www.ncbi.nlm.nih.gov/pubmed/36505827 http://dx.doi.org/10.3389/fonc.2022.1050274 |
work_keys_str_mv | AT libingqing theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT liuxinyuan theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT maotao theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT zhengtaohua theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT zhangpeng theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT zhangqi theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT zhangyu theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT lixiaoyu theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT libingqing researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT liuxinyuan researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT maotao researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT zhengtaohua researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT zhangpeng researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT zhangqi researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT zhangyu researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis AT lixiaoyu researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis |